55.3 F
New York
Thursday, May 26, 2022

CATEGORY

Op-Ed

Canada-based Visionary Education Technology Debuts on Nasdaq with A $17 Million IPO

ocusing on offering high-quality education resources to students around the globe, a Canada-based private education provider, Visionary Education Technology Holdings Group Inc., today made its debut on  Nasdaq under the ticker symbol “VEDU.”

Shineco, Inc. to Build Its First Tumor Classification Diagnosis and Treatment Center in Weifang City, China

The Company expects to complete the construction of its first city-level tumor classification diagnosis and treatment center by the end of 2022.

The SEC identifies 5 Chinese companies for potential delisting

n Thursday after the regulatory agency identified five Chinese companies for potential delisting from US exchanges due to inadequate disclosures.

Lakeshore Acquisition II prices $60M IPO, trading starts on March 9th

Blank check company Lakeshore Acquisition II Corp. (the "Company"), led by Chairman and CEO Bill Chen, priced its initial public offering of 6,000,000 units at an offering price of $10.00 per unit.

Amazon announces 20-for-1 stock split, $10 billion buyback

Amazon announced on Wednesday that its board had approved a 20-for-1 stock split and authorized a $10 billion buyback of the internet retailers' shares,...

Shineco, Inc. to Create A New Platform for Psychological Rehabilitation of Tumor Patients

the Platform to conduct research on critical topics, introduce the results of relevant research into the Company's tumor clinical treatment system, and improve the development of Shineco's digital tumor diagnosis and treatment.

Shineco, Inc. Announces Strategic Alliance to Enhance the R&D of Innovative Drugs and Medical Devices

Both Shineco and JSY are poised to seize these opportunities to increase market share in the innovative drug and medical device industry by relying on their business advantages and their synergy cooperation. 

Shineco, Inc. Enters Cooperation Agreement to Explore High-end Medical Imaging Devices Field and Produce PET

Both parties will produce 100 PET tumor precision imaging inspection devices within 2022, and it is expected to achieve sales revenue of RMB750 million (approximately $118 million).

Shineco, Inc. Appoints Professor Qiyin Sun as Chief Medical Consultant

Professor Sun will lead the research and innovation of the company’s tumor treatment and provide technical consultation in early tumor screening and tumor radiotherapy to support the commercialization of digital tumor diagnosis and treatment.

Interview with Dr. Peng He: why invest in the digital medical market and cancer prevention and treatment?

technological development, market evolution, and the COVID-19 pandemic, digital medical and healthcare management industries are ushering in significant development opportunities.

Latest news